Dosimetric comparison of intensity modulated and volumetric arc radiation therapy for gastric cancer

ZHIPING LI*, JIANSHUANG ZENG*, ZI WANG, HONG ZHU and YUQUAN WEI

1Department of Abdominal Oncology, Cancer Center of West China Hospital; 2State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China

Received September 1, 2013; Accepted May 7, 2014
DOI: 10.3892/ol.2014.2363

Abstract. The aim of the present study was to compare radiotherapy treatment plans for gastric cancer using intensity-modulated radiotherapy (IMRT) and single/double-arc volumetric modulated arc therapy (SA/DA-VMAT) delivery techniques. A total of 29 postoperative gastric cancer patients were enrolled in this study and each patient was scheduled 5-field IMRT (5F-IMRT), 7-field IMRT (7F-IMRT), SA-VMAT and DA-VMAT techniques. Dose-volume histogram statistics, conformal index (CI), homogeneity index (HI) and monitor units (MUs) were analyzed to compare treatment plans. The DA-VMAT plans exceeded the other three methods in terms of planning tumor volume dose and organs at risk in the kidneys, but not in the liver. DA-VMAT exhibited a better mean CI (0.87±0.03) and HI (0.10±0.01) than the other techniques. In addition, for the kidneys the dose sparing (V13, V18 and mean kidney dose) was improved by DA-VMAT plans. Similar results were observed for MUs. However, 5F-IMRT showed a marginal advantage in V30 and mean dose in normal liver when compared with DA-VMAT. The results of this study suggest that DA-VMAT provides improved tumor coverage when compared with 5F-IMRT, 7F-IMRT and SA-VMAT; however, DA-VMAT exhibits no advantage in liver protection when compared with 5F-IMRT. Further studies are required to establish differences in treatment outcomes among the four technologies.

Introduction

Gastric cancer is the fourth most common type of malignant tumor worldwide (1) and the annual number of novel cases is ~95 million. Each year ~70 million individuals succumb to gastric cancer, which makes it the second most common cause of cancer-related mortality worldwide (2). Since the SWOG/INT-0116 trial (3) in 2001, adjuvant chemoradiotherapy has become an established standard treatment for gastric cancer. In contrast to the INT-0116 trial, which included D0- or D1-resected gastric cancer patients, Kim et al (4) studied D2-resected participants using the same chemoradiotherapy regimens, and also demonstrated that concurrent chemotherapy increased survival and reduced recurrence.

However, compared with surgery alone, postoperative chemoradiotherapy significantly increased toxicity in patients. In the INT-0116 study, 57% of patients experienced grade 3 or 4 toxicity (3). Ringash et al (5) found that the application of three-dimensional conformal radiotherapy (3D-CRT) in patients with gastric cancer, which is different from the 2D radiotherapy used in the INT-0116 trial, decreased the incidence of grade 2 or higher toxicity to 25%. Similar studies have shown that conformal intensity-modulated radiation therapy (IMRT) achieves superior planning tumor volume (PTV) target coverage and improved normal tissue sparing (6-8). Furthermore, although the National Comprehensive Cancer Network Guidelines recommend either 3D-CRT or IMRT, it is now widely accepted in the medical profession that IMRT is superior to 3D-CRT in terms of tumor coverage, increased local tumor control probability and dose reduction to certain organs at risk (OARs).

Volumetric modulated arc therapy (VMAT), as a modified version of IMRT, employs the linear accelerators Elekta Synergy VMAT and Elekta Precise (Elekta Oncology Systems, Crawley, UK) to conduct dynamic modulation rotational radiotherapy. The advantages of VMAT when compared with IMRT, include a reduction in the number of monitor units (MUs), shorter delivery times and lower exposure of OARs. In practice, the VMAT optimization depends on the number of arcs and the gantry angle spacing between subsequent control points. At present, controversy exists as to whether a single arc VMAT can achieve dose distributions comparable to IMRT plans. Bertelsen et al (9) demonstrated that single arc is sufficient to achieve a plan quality similar to IMRT, however, Guckenberger et al (10) have reported that it is dependent on the complexity of the target volume.

VMAT is considered to be equivalent or superior to IMRT for certain malignancies, including head and neck, prostate,
lung, cervical and pancreatic cancer (11), however, a lack of comprehensive comparison between IMRT to VMAT exists with regards to gastric cancer treatment. Therefore, the present study aimed to elucidate the dosimetric quality of single-arc (SA)/double-arc (DA)-VMAT for gastric cancer, compared with 5-field IMRT (5F-IMRT) and 7-field IMRT (7F-IMRT).

Patients and methods

Patient samples. A total of 29 patients with nonmetastatic gastric or gastroesophageal (GE) junction cancer who received radiotherapy treatment at the West China Hospital (Chengdu, China) between February 2012 and August 2012 were included in the study. All patients were confirmed by pathology and disease was limited to the stomach or GE junction and regional lymph nodes. Patients were staged according to the American Joint Committee on Cancer staging system (7th edition) (12). Each patient was rescheduled retrospectively via inverse planning 5F-IMRT, 7F-IMRT, SA-VMAT and DA-VMAT techniques using Pinnacle treatment planning systems (TPS; Philips Medical Systems, Fitchburg, WI, USA). Patient characteristics are summarized in Table I. Patients provided written informed consent.

Immobilization, simulation and target delineation. All patients were immobilized in a supine position, with arms crossed above the head using a thermoplastic shell. Intravenous contrast-enhanced computed tomography (CT)-simulation was performed at 3 mm intervals of abdomen using Gemini GXL positron emission tomography/CT (Philips Medical Systems). Respiratory control and abdominal compression were not used. Following simulation, the CT images were transferred to the Pinnacle3 version 9.2 radiation treatment planning system (Philips Medical Systems). The clinical target volume (CTV) included tumor bed and perigastric lymph nodes, following the recommendations outlined in the INT-0116 trial (3). Paracardial, splenichilum, paraaortic, celiac, paraesophageal, hepatic portal, pancreaticoduodenal and splenic hilum lymph nodes were included if deemed as high risk, based on the pathologically involved regional lymph nodes and the primary tumor location. The CTV to PTV expansion was typically 5-10 mm to account for daily setup error and organ motion. Normal structures, including the spinal cord, liver, colon, duodenum, small intestine and kidneys were also contoured. All the contours were drawn by the same physician. Each patient had one 5F-IMRT, one 7F-IMRT, one SA-VMAT and one DA-VMAT plan created by the same radiation therapist. The same dose constraints were used for creation of 5F-IMRT, 7F-IMRT, SA-VMAT and DA-VMAT plans (Table II).

All generated plans for each patient consisted of 50.4 Gy to be delivered to PTV in 28 fractions. The objective of planning was to deliver the prescribed dose to ≥95% of the PTV with a dose range that did not exceed -10 and +15% of the prescribed dose. All plans were generated for the Elekta Beam Modulator (Elekta Oncology Systems).

Treatment planning and optimization; 5F-IMRT and 7F-IMRT. The IMRT optimization was performed using the direct machine parameter optimization algorithm in the treatment planning system (Pinnacle3; Philips Radiation Oncology Systems). IMRT uses five and seven coplanar beams; five beam beam irradiation, angles of 25, 60, 95, 180 and 315°; or seven beam irradiation, angles of 0, 51, 102, 153, 204, 255 and 306°. In the plan generation, the maximum iterations in the plan optimization were 80. There were no limitations with regard to the MUs per segment. Plans were generated for the Elekta Beam Modulator with 6-MV.

SA-VMAT. The single arc VMAT planning was performed using the SmartArc planning algorithm in Pinnacle3 version 9.2 (Philips Radiation Oncology Systems). The single arc VMAT was planned with a beam delivery time ≤240 sec, and with an arc from 181-180° (a control point every 4°). The accelerator used automatic dose rate selection, which ensured that the
Table II. OARs dose constraints.

| OARs        | Prescribed dose limit |
|-------------|-----------------------|
| Spinal Cord | D$_{95}$$\leq$40 Gy  |
| Liver       | V$_{30}$$\leq$30%    |
| Kidney      | V$_{13}$$\leq$50%    |
|             | V$_{18}$$\leq$33%    |
| Small intestine | D$_{max}$$\leq$50 Gy |
|             | V$_{50}$$\leq$10%    |
|             | V$_{45}$$\leq$15%    |
| Duodenum    | D$_{max}$$\leq$50 Gy |
|             | V$_{50}$$\leq$10%    |
|             | V$_{45}$$\leq$15%    |

V$_{\alpha}$, percentage of volume receiving at least $\alpha$ Gy; OARs, organs at risk.

maximal possible dose rate was selected for each individual segment of the arc. The initial step was performed using the SmartArc algorithm to obtain the optimal modulated fluency. In the second step, the segments were optimized based on the small target areas receiving insufficient irradiation dose, using the same algorithm. Plans were generated with 6-MV.

**DA-VMAT.** The plans were optimized in the same planning system as mentioned previously. The double arc VMAT was planned with a beam delivery time of $\pm 120$ sec x 2, and with a gantry rotation of 181-180-181° (a control point every 4°). Plans were generated with 6-MV and all the objective parameters and algorithm used were the same as that for the single arc VMAT. All the plans were repeatedly optimized until the objectives were met.

**Evaluation of the dose-volumetric histogram (DVH)-based parameters.** For the PTV, D$_{95}$, D$_{max}$, D$_{3}$ and D$_{2}$, where D is the accepting dose and n is the percentage of the PTV, were selected to comply with the International Commission on Radiation Units and Measurements Report No. 83 (13). The conformal index (CI) and homogeneity index (HI) for PTV were calculated. The CI was defined as follows: CI = cover factor (the percentage of the PTV volume receiving 50.4 Gy) × spill factor (the volume of the PTV receiving the 50.4 Gy relative to the total prescription dose-volume). The HI was defined as follows: HI = the minimum dose in 5% of the PTV (D$_{5}$) / minimum dose in 95% of the PTV (D$_{95}$). The following dosimetric parameters were retrospectively analyzed: Volumes of kidney receiving a dose of $\geq$13 and 18 Gy (V13 and V18); volumes of liver receiving a dose of $\geq$30 Gy; D$_{2}$ of the spinal cord; volumes of small intestine and colon receiving a dose of $\geq$50 Gy (V50); the mean dose to OARs and remaining volume at risk; the maximum dose to 1.5 and 10 cm$^2$ of the pancreas and duodenum; and the volume of pancreas and duodenum receiving 5, 10, 15, 20, 25, 30, 35, 40, 45, and 50 Gy.

**Statistical analysis.** The data were analyzed using SPSS software, version 16.0 (SPSS, Inc., Chicago, IL, USA) and all data are presented as the mean ± standard deviation. The Wilcoxon's signed rank test was performed and P<0.05 was considered to indicate a statistically significant difference.

**Results**

**PTV coverage.** The evaluation of the DVH-based parameters of the PTV is shown in Table III. The D$_{95}$ and D$_{max}$ of the PTV were similar among the 5F-IMRT, 7F-IMRT, SA-VMAT and DA-VMAT plans, respectively, and no significant differences were identified (P>0.05). For the PTV coverage, the mean CI of the DA-VMAT plans (0.87±0.03) was significantly higher than that of 5-IMRT (0.86±0.02), 7-IMRT (0.86±0.02) and SA-VMAT (0.83±0.03), respectively (P<0.05). Additionally, the mean HI of the DA-VMAT plans (0.10±0.01) was found to be significantly improved when compared with those in 5-IMRT (0.13±0.17), 7-IMRT (0.10±0.02) and SA-VMAT (0.12±0.02), respectively (P<0.05). DA-VMAT plans also exhibited a lower D2 (54.21±49.92) when compared with the 5-IMRT (54.52±43.27), 7-IMRT (54.54±57.63) and SA-VMAT (55.33±109.69) plans (P<0.05). A typical dose distribution in the transverse section is shown in Fig. 1.

For the other OARs (Table V), no significant differences in dose were identified among the four methods, with the exception of the marginal edge in D2 for the duodenum with DA-VMAT. The mean doses to the normal liver for each method were 21.90±138.97 Gy (DA-VMAT), 23.42±194.66 Gy (SA-VMAT), 21.91±147.73 Gy (7F-IMRT) and 19.82±196.08 Gy (5F-IMRT), with the mean dose to the normal liver with 5F-IMRT found to be the lowest. Furthermore, the V30 Gy (%) with SA-VMAT (0.22±0.05) was higher than that with 5F-IMRT (0.19±0.03) (P<0.05), 7F-IMRT (0.19±0.03) (P<0.05) and DA-VMAT (0.19±0.03) (P<0.05). The results are shown in Table IV.

**Discussion**

As mentioned previously, adjuvant chemoradiotherapy for resectable gastric adenocarcinoma has become the standard treatment for D0 and D2 gastrectomy. However, due to the combination of radiotherapy and chemotherapy, treatment-associated toxicities are enhanced, which often leads to relinquishment of treatment among patients. A number of studies on dosimetric comparison of 3D-CRT and IMRT have shown that IMRT exhibits improved OAR sparing. Few studies have investigated the application of VMAT in treating postoperative gastric cancer patients (14).

It is known that the complexity of the target volume and the number of VMAT arcs are major determinants of whether
Table III. Comparisons of the dose-volume histogram-based parameters of the planning tumor volume.

| Parameters | 5F-IMRT | 7F-IMRT | SA-VMAT | DA-VMAT | P-value |
|------------|---------|---------|---------|---------|---------|
| D98, Gy    | 49.10±0.57 | 49.12±0.59 | 49.06±0.51 | 49.11±0.46 | 0.680 0.363 0.624 0.180 0.280 0.524 |
| D95, Gy    | 50.35±0.44 | 50.34±0.41 | 50.41±0.38 | 54.21±0.50 | 0.870 0.104 0.446 0.070 0.480 0.380 |
| D50, Gy    | 51.10±8.81 | 52.60±0.50 | 53.43±0.54 | 52.81±0.43 | 0.219 <0.001 0.944 <0.001 0.380 <0.001 |
| D2, Gy     | 54.52±0.43 | 54.54±0.57 | 55.33±1.10 | 54.21±0.50 | 0.834 <0.001 0.001 <0.001 <0.001 <0.001 |
| CI         | 0.86±0.02  | 0.86±0.02  | 0.83±0.03  | 0.87±0.03  | 0.994 <0.001 0.012 <0.001 0.010 <0.001 |
| HI         | 0.13±0.17  | 0.10±0.02  | 0.12±0.02  | 0.10±0.01  | 0.715 0.003 0.013 <0.001 0.030 <0.001 |

n=29. CI, conformal index; HI, homogeneity index; 5F-IMRT, 5-field intensity-modulated radiotherapy; 7F-IMRT, 7-field intensity-modulated radiotherapy; SA-VMAT, single-arc volumetric modulated arc therapy; DA-VMAT, double-arc volumetric modulated arc therapy.

Table IV. Comparisons of the dose-volume histogram-based parameters of the kidneys and liver in present study.

| OARs      | 5F-IMRT | 7F-IMRT | SA-VMAT | DA-VMAT | P-value |
|-----------|---------|---------|---------|---------|---------|
| Left kidney |         |         |         |         |         |
| V13       | 0.38±0.05 | 0.39±0.04 | 0.41±0.04 | 0.36±0.04 | 0.539 0.039 0.010 0.075 0.001 <0.001 |
| Mean dose, Gy | 15.42±1.93 | 14.96±1.91 | 15.68±1.98 | 14.44±1.58 | 0.159 0.680 0.003 0.153 0.080 0.010 |
| Right kidney |         |         |         |         |         |
| V13       | 0.36±0.06 | 0.34±0.05 | 0.33±0.05 | 0.27±0.06 | 0.053 0.016 <0.001 0.479 <0.001 <0.001 |
| Mean dose, Gy | 12.83±2.15 | 12.83±2.03 | 12.62±2.10 | 11.23±1.88 | 0.680 0.529 0.001 0.780 0.001 0.008 |
| Liver     |         |         |         |         |         |
| V30       | 0.19±0.03 | 0.19±0.03 | 0.22±0.05 | 0.19±0.03 | 0.592 0.013 0.895 0.038 0.762 0.018 |
| Mean dose, Gy | 19.82±1.96 | 21.92±1.48 | 23.42±1.95 | 21.90±1.39 | <0.001 <0.001 <0.001 0.002 0.721 0.001 |

5F-IMRT, 5-field intensity-modulated radiotherapy; 7F-IMRT, 7-field intensity-modulated radiotherapy; SA-VMAT, single-arc volumetric modulated arc therapy; DA-VMAT, double-arc volumetric modulated arc therapy.
VMAT is advantageous when compared with IMRT (11). In contrast to the studies on head and neck cancer mentioned previously (9,15), certain studies on cervical cancer (16) and benign intra-cranial tumors (17) have demonstrated that SA-VMAT is superior or equivalent to IMRT. However, in contrast to these studies, less complexity was identified in target volume for gastric cancer with one dose level than that for head and neck cancer with two or three dose levels (15,18). In addition, the OARs in gastric cancer radiotherapy were found to be more radiosensitive than that in cervix uteri radiotherapy (18,19). As expected, the data in the present study indicated that the treatment planning for gastric cancer DA-VMAT plans achieved superior dose coverage for PTV (CI and HI were improved; P<0.05). Regarding HI, SA-VMAT exhibited an advantage when compared with 5F-IMRT, but not 7F-IMRT. For the CI, the SA-VMAT exhibited no advantage when compared with IMRT.

It is known that the kidney is a radiosensitive organ and that damage to the kidneys is an inevitable side effect of pelvic or abdominal radiotherapy. Previous studies (20,21) have suggested that total doses of 18-23 Gy and 28 Gy in 0.5-1.25 Gy/fractions may be associated with a 5 and 50% risk of injury in five years, respectively. Jansen et al (22) conducted a prospective study analyzing kidney function in 44 gastric cancer patients following abdominal irradiation and observed an 11 and 52% decrease in left renal function after six months and 18 months, respectively. The V20 (left kidney) and mean left kidney dose were identified as parameters associated with decreased kidney function. Therefore, in the present study V13 and V18 Gv were selected as indicators. The doses to the kidneys were significantly decreased in DA-VMAT plans; however, the V13 Gy, V18 Gy and D_{mean} in the left kidney were generally higher than those of the right kidney. One reason for this may be that the majority of the left kidney is located in the superior section of the target volume.

In order to optimize dose distribution in the tumor bed, which is anterior to the left kidney, it is difficult for TPS to reduce the irradiation dose to the left kidney. By contrast, the right kidney is located in the lower section which is the paraaortic lymph node region. Since it is much smaller and more regular than the upper section, it is easier to complete dose computation.

For patients in China, radiation-induced liver disease (RILD) must be considered. As a parallel organ, the radiation injury to the liver is found to positively correlate with the volume and dosage of radiation to the normal hepatic tissues. Emami et al (23) reported that TD5/5 (the tolerance dose leading to a 5% complication rate at five years) for one-third, two-thirds and the whole liver at one dose of 8-2 Gy/day were 50, 35 and 30 Gy, respectively. However, these data were predominantly obtained from clinical practice in North America and may not apply to the situation in China. Based on a national seroepidemiological survey, the carrier rate of HBsAg in China among 1- to 59-year-olds is 7.18% and among the medically examined individuals in Chengdu, the HBsAg positive rate is 6.1% (24). At present, there is no constraint on the standard dose for those vulnerable patients.

The incidence of RILD is significantly associated with mean dose to normal liver (MDTNL) which may be a predictor of RILD. In a study that investigated the dose-volume tolerance for RILD using the Lyman-Kutcher-Burman normal tissue complication probability model, it was found that no cases of RILD were identified when the mean liver dose was <31 Gy (25). Each 1 Gy increase in MDTNL exhibited a 4% increase in the incidence of RILD. Furthermore, at an MDTNL of 43 Gy the incidence was as high as 50%. Liang et al (26) demonstrated that when the MDTNL was 23 and 31 Gy, the RILD occurrence rate was 6 and 69%, respectively. In addition, a MDTNL of 23 Gy may be used as a predictor of RILD. Furthermore, the

![Figure 1. Dose distribution in a typical transverse slice. Planning tumor volume is presented as light-blue color wash. The red, green, pink, yellow, orange and indigo lines represent isodose curves of 50.4, 45.36, 30, 23, 18 and 13 Gy, respectively.](image-url)
Table V. Comparisons of the dose-volume histogram-based parameters of the other organs at risk and MUs in present study.

| OARs          | 5F-IMRT | 7F-IMRT | SA-VMAT | DA-VMAT | P-value |
|---------------|---------|---------|---------|---------|---------|
|               |         |         |         |         | 5F-IMRT vs. 7F-IMRT | 5F-IMRT vs. SA-VMAT | 5F-IMRT vs. DA-VMAT | 7F-IMRT vs. SA-VMAT | 7F-IMRT vs. DA-VMAT | SA-VMAT vs. DA-VMAT |
| Small intestine |         |         |         |         |         |         |         |         |         |         |
| D<sub>2</sub>, Gy | 48.22±9.46 | 48.67±9.43 | 49.55±9.53 | 48.58±9.38 | 0.499 | 0.044 | 0.686 | 0.137 | 0.846 | 0.107 |
| V50%          | 0.04±0.03 | 0.04±0.03 | 0.05±0.03 | 0.04±0.03 | 0.721 | 0.237 | 0.750 | 0.312 | 0.889 | 0.327 |
| Mean dose, Gy | 17.19±6.26 | 16.50±5.76 | 18.01±6.34 | 16.90±5.92 | 0.658 | 0.613 | 0.858 | 0.301 | 0.762 | 0.388 |
| Colon         |         |         |         |         |         |         |         |         |         |         |
| D<sub>2</sub>, Gy | 51.38±2.87 | 51.54±2.94 | 52.51±2.47 | 51.46±2.93 | 0.703 | 0.018 | 0.715 | 0.040 | 0.932 | 0.042 |
| V50%          | 0.09±0.07 | 0.09±0.07 | 0.11±0.08 | 0.09±0.07 | 0.926 | 0.316 | 0.895 | 0.423 | 0.883 | 0.347 |
| Mean dose, Gy | 22.39±5.07 | 21.47±4.42 | 23.50±5.66 | 22.57±5.19 | 0.539 | 0.397 | 0.950 | 0.159 | 0.451 | 0.451 |
| Spinal cord   |         |         |         |         |         |         |         |         |         |         |
| D<sub>2</sub>, Gy | 38.98±2.41 | 38.90±2.29 | 39.08±4.44 | 38.50±3.18 | 0.950 | 0.432 | 0.686 | 0.410 | 0.762 | 0.347 |
| Pancreas      |         |         |         |         |         |         |         |         |         |         |
| D<sub>1</sub>cm<sup>3</sup>, Gy | 54.52±0.70 | 54.51±1.03 | 55.38±1.16 | 54.13±0.57 | 0.834 | 0.002 | 0.004 | 0.005 | 0.003 | <0.001 |
| D<sub>5</sub>cm<sup>3</sup>, Gy | 53.92±0.47 | 54.02±0.60 | 54.84±0.99 | 53.73±0.54 | 0.646 | <0.001 | 0.059 | <0.001 | 0.006 | <0.001 |
| D<sub>10</sub>cm<sup>3</sup>, Gy | 53.53±0.48 | 53.70±0.56 | 54.50±0.94 | 53.47±0.54 | 0.312 | <0.001 | 0.280 | <0.001 | 0.024 | <0.001 |
| V5%           | 0.99±0.01 | 0.99±0.02 | 0.97±0.17 | 1.00±0.01 | 0.601 | 0.975 | 0.992 | 0.601 | 0.782 | 0.795 |
| V10%          | 0.98±0.05 | 0.98±0.06 | 0.98±0.06 | 0.98±0.06 | 0.885 | 0.680 | 0.687 | 0.809 | 0.830 | 0.970 |
| V15%          | 0.97±0.08 | 0.97±0.08 | 0.98±0.08 | 0.97±0.09 | 0.639 | 0.664 | 0.841 | 0.986 | 0.782 | 0.795 |
| V20%          | 0.97±0.09 | 0.97±0.09 | 0.97±0.09 | 0.97±0.09 | 0.696 | 0.935 | 0.872 | 0.626 | 0.845 | 0.788 |
| V25%          | 0.96±0.10 | 0.94±0.13 | 0.96±0.09 | 0.96±0.10 | 0.738 | 0.961 | 1.000 | 0.816 | 0.713 | 0.852 |
| V30%          | 0.94±0.10 | 0.94±0.10 | 0.95±0.10 | 0.95±0.10 | 0.797 | 0.845 | 0.743 | 0.685 | 0.477 | 0.814 |
| V35%          | 0.92±0.11 | 0.92±0.11 | 0.93±0.11 | 0.93±0.11 | 0.907 | 0.785 | 0.618 | 0.767 | 0.613 | 0.767 |
| V40%          | 0.89±0.12 | 0.89±0.12 | 0.90±0.12 | 0.90±0.12 | 0.907 | 0.709 | 0.756 | 0.658 | 0.785 | 0.919 |
| V45%          | 0.85±0.13 | 0.85±0.13 | 0.86±0.13 | 0.86±0.13 | 0.969 | 0.504 | 0.803 | 0.608 | 0.876 | 0.810 |
| V50%          | 0.76±0.16 | 0.77±0.15 | 0.78±0.15 | 0.78±0.15 | 0.870 | 0.570 | 0.774 | 0.703 | 0.797 | 0.810 |
| Mean dose, Gy | 48.02±7.12 | 48.15±6.82 | 49.93±4.52 | 49.27±4.42 | 0.969 | 0.138 | 0.602 | 0.146 | 0.750 | 0.216 |
| Duodenum      |         |         |         |         |         |         |         |         |         |         |
| D<sub>1</sub>cm<sup>3</sup>, Gy | 53.11±1.59 | 53.15±1.36 | 53.93±1.77 | 53.02±1.41 | 0.762 | 0.036 | 0.534 | 0.036 | 0.786 | 0.017 |
| D<sub>5</sub>cm<sup>3</sup>, Gy | 50.84±4.20 | 51.03±3.30 | 51.79±4.36 | 50.83±4.41 | 0.703 | 0.041 | 0.994 | 0.020 | 0.738 | 0.039 |
| D<sub>10</sub>cm<sup>3</sup>, Gy | 46.97±9.57 | 46.87±9.19 | 48.05±9.49 | 46.78±9.97 | 0.715 | 0.174 | 0.994 | 0.107 | 0.663 | 0.225 |
| V5%           | 0.88±0.16 | 0.88±0.16 | 0.89±0.15 | 0.89±0.16 | 0.890 | 0.942 | 0.961 | 0.821 | 0.885 | 0.859 |
| V10%          | 0.83±0.19 | 0.83±0.19 | 0.84±0.18 | 0.83±0.19 | 0.912 | 0.869 | 0.950 | 0.832 | 0.912 | 0.826 |
| V15%          | 0.81±0.21 | 0.81±0.20 | 0.82±0.20 | 0.81±0.20 | 0.895 | 0.761 | 0.839 | 0.679 | 0.851 | 0.778 |
risk of hepatitis B virus (HBV) radiotherapy reactivation has been identified, which must be considered. Previous study has revealed that radiotherapy is a significant risk factor to RILD in patients with postgastrectomy adenocarcinoma carrying HBV (27). For those patients, a reduction in volume and dosage of radiation to the normal hepatic tissues, as well as frequent monitoring of liver function and routine detection of the HBV-DNA copy numbers, are required. If necessary, regular antiviral treatment should be provided. In the present study, only the MDTNL of SA-VMAT plans exceeded 23 Gy and 5F-IMRT plans provided improved sparing of the liver with a marginal advantage when compared with SA-VMAT.

In addition, the dosimetric parameters of the duodenum and pancreas were compared among the four technologies. Anatomically, the duodenum is the first section of the small intestine. However, in the practice of radiotherapy, they are different with regard to dose and volume limit. As the duodenum adjoins the stomach, the majority of it is located within the target volume. Additionally, as the duodenum is fixed by the ligament of Treitz, the motion of the duodenum is more limited than that of the rest of the small bowel. In a dose escalation trial of pancreatic cancer, Singh et al. (28) revealed that the volume of duodenum receiving a dose of >80% of the prescribed dose was greater than the remaining small bowel; however, individual variations were significant. Therefore, reducing the dose received by the duodenum is an important issue. Severe gastrointestinal (GI) toxicity appears to be the main dose-limiting factor in abdominal radiotherapy and it may be one of the reasons why the IMRT is superior to 3D-CRT in terms of OARs sparing. However, in practice, there is no difference in acute GI toxicity grade 2 between IMRT and 3D-CRT. In a previous study, the acute grade 2 or greater GI toxicity was found to be 61.5 and 61.2% for 3D-CRT and IMRT, respectively (7). According to Liu et al. (14), the acute toxicity was 56 and 54% for the IMRT and 3D-CRT groups, respectively. At present, studies investigating dose constraints of the duodenum are rare. Huang et al. (29) have suggested that the V25 Gy of the duodenum is the best predictor for GI toxicity in pancreatic cancer patients with concurrent gemcitabine-erlotinib and radiotherapy. The 12-month GI toxicity rates were found to be 8 and 48% for V25 Gy ≤45% and V25 Gy≥ 45%, respectively (P=0.03). Excluding the erlotinib group, the V35 Gy was the best predictor and the 12-month GI toxicity rates were 0 and 41% for V35 Gy ≤20% and V35 Gy ≥20%, respectively (P=0.04). Although chemotherapeutics are different in the treatment of gastric cancer and pancreatic cancer, the indicators remain useful. In conclusion, in the present study, all four technologies reached the standard for the indicator of V25 Gy ≤45%, however, for V35 Gy ≥0%, all technologies failed. This analysis is only a preliminary step and, thus, further study is required to improve the sparing of the duodenum and identify dosimetric predictors for GI toxicity.

The manner in which the pancreas may be protected during abdominal radiotherapy is another issue which remains unclear. Similar to the duodenum, the motion of the pancreas is limited and the majority of it is within the target volume. Radiation induced damage of the pancreas predominantly decreases the endocrine and exocrine functions of the

Table V. Continued.

| OARs | V20% | V25% | V30% | V35% | V40% | V45% | Mean dose, Gy | MUs | RVR, Gy | MUs, monitor units | RVR, remaining volume at risk |
|------|------|------|------|------|------|------|-------------|-----|--------|-------------------|-----------------------------|
| 5F-IMRT | 0.76±0.22 | 0.76±0.21 | 0.75±0.23 | 0.75±0.24 | 0.75±0.24 | 0.75±0.23 | 36.1±10.15 | 3.46±0.90 | 20.69±1.51 | 20.69±1.51 |
| 7F-IMRT | 0.76±0.22 | 0.76±0.21 | 0.75±0.23 | 0.75±0.24 | 0.75±0.24 | 0.75±0.23 | 36.1±10.15 | 3.46±0.90 | 20.69±1.51 | 20.69±1.51 |
| DA-VMAT | 0.76±0.22 | 0.76±0.21 | 0.75±0.23 | 0.75±0.24 | 0.75±0.24 | 0.75±0.23 | 36.1±10.15 | 3.46±0.90 | 20.69±1.51 | 20.69±1.51 |
| SA-VMAT | 0.76±0.22 | 0.76±0.21 | 0.75±0.23 | 0.75±0.24 | 0.75±0.24 | 0.75±0.23 | 36.1±10.15 | 3.46±0.90 | 20.69±1.51 | 20.69±1.51 |

MUs, monitor units; RVR, remaining volume at risk; 5F-IMRT, 5-field intensity-modulated radiotherapy; 7F-IMRT, 7-field intensity-modulated radiotherapy; DA-VMAT, double-arc volumetric modulated radiotherapy; SA-VMAT, single-arc volumetric modulated radiotherapy.
pancreas (30,31). In the present study, DA-VMAT was found to be marginally more effective than the other three technologies in D1, 5 and 10 cm.

Regarding the issue of how to improve the sparing of OARs, other options are available. Hu et al (32) reported that the dose for postoperative gastric cancer patients may be increased to 54 Gy without increasing the toxicity to critical organs, by using a combination of breath-holding techniques and online image-guided IMRT. However, the problem of controlling gastric emptying remains; patients do not always follow doctor's advice to ensure the GI tract is empty during the course of radiotherapy.

In conclusion, although VMAT has been demonstrated to exhibit advantages in the treatment of other kinds of malignancies, the dosimetric advantage of VMAT in this study was not always evident when compared with IMRT. In addition, it is unclear whether IMRT should be replaced by VMAT. Considering the lower MUs, shorter delivery times and reduced low-dose exposure of OARs, the use of VMAT in postoperative radiotherapy remains suitable for gastric carcinoma; however, the clinical implications and outcome require further study.

References

1. Kamargan F, Dories GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.

2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002, CA Cancer J Clin 55: 74-108, 2005.

3. Macdonald JS, Smallry S, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.

4. Kim S, Lim DH, Lee J, et al: An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 63: 1279-1285, 2005.

5. Ringash J, Khakhsat SJ, Oz A, et al: Post-operative radiochemotherapy for gastric cancer: adoption and adaptation. Clin Oncol (R Coll Radiol) 17: 91-95, 2005.

6. Alani S, Soyfer V, Strauss N, Schifter D and Corn BW: Limited advantages of intensity-modulated radiotherapy over 3D conformal radiation therapy in the adjuvant management of gastric cancer. Int J Radiat Oncol Biol Phys 74: 562-566, 2009.

7. Minn AY, Hsu A, La T, et al: Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer 116: 3943-3952, 2010.

8. Dahele M, Skinner M, Schultz B, Cardoso M, Bell C and Ung YC: Adjuvant radiotherapy for gastric cancer: A dosimetric comparison of 3-dimensional conformal radiotherapy, tomotherapy and conventional intensity modulated radiotherapy treatment plans. Med Dosim 35: 115-121, 2010.

9. Bertelsen A, Hansen CR, Johansen J and Brink C: Single arc volumetric modulated arc therapy of head and neck cancer. Radiother Oncol 95: 142-148, 2010.

10. Guckenberger M, Richter A, Krieger T, Wilbert J, Baier K and Flentje M: Is a single arc sufficient in volumetric-modulated arc therapy (VMAT) for cervical cancer: Planning study of the ICRU 10: 1, 2010.

11. Alvarez-Moret J, Poil F, Koebel O and Dobler B: Evaluation of volumetric modulated arc therapy (VMAT) with Oncentra MasterPlan for the treatment of head and neck cancer. Radiat Oncol 5: 110, 2010.

12. Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.

13. International Commission of Radiation Units and Measurements: ICRU report 83: Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT). Journal of the ICRU 10: 1, 2010.

14. Liu GF, Bair RJ, Bair E, Liaw SL, and Kosh Y: Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy, PLoS One 9: e82642, 2014.

15. Stieler F, Wolff D, Schmid H, et al: A comparison of several modulated radiotherapy techniques for head and neck cancer and dosimetric validation of VMAT. Radiother Oncol 101: 388-393, 2011.

16. Cozzi L, Dinshaw KA, Shrivastava SK, et al: A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for crux uteri radiotherapy. Radiother Oncol 89: 180-191, 2008.

17. Fogliata A, Clivio A, Nicolini G, Vanetti E and Cozzi L: Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques. Radiother Oncol 89: 254-262, 2008.

18. Wang X, Li G, Zhang Y, et al: Single-arc volumetric-modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer: Dosimetric comparisons with three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT). Med Dosim 38: 395-400, 2010.

19. Mundishita K, Kitamura N, Machida H, et al: The impact of vircency mesh sheet placed on pelvic wall for reducing the irradiated bowel volume in VMAT of cervical cancer: Planning study. Int J Radiat Oncol Biol Phys 84: S430-S431, 2012.

20. Peschel RE, Chen M and Seashore J: The treatment of massive hepatomegaly in stage IV-S neuroblastoma. Int J Radiat Oncol Biol Phys 7: 549-553, 1981.

21. Cassidy JR: Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 31: 1249-1256, 1995.

22. Jansen EPM, Saunders MP, Boot H, et al: Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 67: 781-785, 2007.

23. Emami B, Lyman J, Brown A, et al: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21: 109-122, 1991.

24. Wang YB, Chen EQ, Cui YL, Zeng L, Wang YJ and Tang H: Seroreprevalece of hepatitis B virus markers in individuals for physical examination in West China Hospital, China. Eur Rev Med Pharmacol Sci 15: 592-596, 2011.

25. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS and Ten Haken RK: Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53: 810-821, 2002.

26. Liang SX, Zhu XD, Xu ZY, et al: Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 65: 426-434, 2006.

27. Xu J, Zhu H, Zhao Y, et al: Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma. Oncol Lett 4: 471-476, 2012.

28. Singh AK, Tierney RM, Low DA, et al: A prospective study of differences in duodenum compared to remaining small bowel motion between radiation treatments: Implications for radiation dose escalation in carcinoma of the pancreas. Radiat Oncol 1: 33, 2006.

29. Huang J, Robertson JM, Ye H, Margolis J, Nadeau L and Yan D: Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 83: 1120-1125, 2012.

30. Ahmadu-Suka F, Gillette EL, Withrow SJ, Husted PW, Nelson AW and Whiteman CE: Exocrine pancreatic function following intraoperative irradiation of the canine pancreas. Cancer 62: 1091-1095, 1988.

31. Yamaguchi K, Nakamura K, Kimura M, et al: Intraoperative radiation enhances decline of pancreatic exocrine function after pancreatic head resection. Dig Dis Sci 45: 1084-1090, 2000.

32. Hu Y, Ye J, Wang J, Xu Q and Zhang Z: Incorporating breath holding and image guidance in the adjuvant gastric cancer radiotherapy: a dosimetric study. Radiother Oncol 7: 98, 2012.